Streamlining PRMS Microprocesses: A Collaborative Guide to Reduce Study Activation Timelines and Increase Accrual by Prioritizing Review Assessments through Continual Monitoring

UTSouthwestern

Harold C. Simmons Comprehensive Cancer Center



Tiffany Levine, MBA; Angelia Riley, MSHS; Chastity Escalante, MBA; Taler Jefferson, MS; Erin Williams, MBA; Jacqueline Quivers, MS, Kevin Courtney, MD, PhD UT Southwestern Medical Center – Harold Simmons Comprehensive Cancer Center

BACKGROUND

- The Protocol Review and Monitoring System (PRMS) plays a critical role in ensuring the scientific integrity and regulatory compliance of clinical trials.
- In 2023, SCCC participated in the Performance Excellence and Quality Management (PExQM) project, a lean Six Sigma project initiative at the University of Texas Southwestern Medical Center (UTSW) in which the overall goal was to identify focal tasks in 2024 for improvement.
- The project resulted in a streamlining of PRMS submission and review processes between the Protocol Review and Monitoring Committee (PRMC), Human Research Protection Program (HRPP), feasibility committee, and disease-oriented teams (DOTs).
- Key challenges discovered at pre-submission phase for study submission to final PRMC approval included submission errors and inefficient tracking of stipulations which contributed to prolonged approval timelines.
- To improve efficiency in these microprocesses, it is essential to reduce submission errors, prioritize review assessments, and increase stakeholder knowledge of PRMS submission requirements.

GOALS

- 1. Provide DOTs with clear guidance to minimize errors and produce more compliant study submission packets.
- 2. Establish standardized procedures to expedite response to stipulations and reduce review to approval timelines.
- 3. Tighten parallel review processes between the PRMC and the IRB.
- 4. Utilize stakeholder meetings to monitor the study activation pipeline.
- 5. Continuous monitoring of trials once activated to increase accrual progress and provide regular feedback.
- 6. Create training tools and resources for cleaner submissions.
- 7. Decrease need for repetitive review of trials by the PRMC and IRB.

SOLUTIONS AND METHODS

- 1. Revised electronic submission forms to decrease the number of incomplete forms submitted for PRMC review.
- 2. Hosted new staff training conducted specifically by the PRMC Sr. Program Coordinators via video conference and provided educational materials.
- 3. Developed review metrics for timelines related to the parallel processes for the PRMC and IRB.
- 4. Explored solutions for PRMC review of trials that can be fast tracked.
- 5. Modified Simmons Comprehensive Cancer Center protocol template to streamline scientific review of data and objectives.

Suppliers Outputs Requirements Process Customers Inputs - PRMC - Pharmaceutical PRMC approval Principal - Pharmaceutical see below is required for Company Companies Investigator - DOT Manager Pharmaceutical inal IRB approval **PRMC** - DOT/PI Complete PRMC - PC Team Company submission Packet - Regulatory (stipulation with essential - PRMC response) - Regulatory documents **Step 1: Step 3: Step 2: Step 4:** <u>Step 5:</u> Complete initial PRMC assigns PRMC Within 3 days Regulatory trial submission final Approval. after review, review; Associate in IRB within 17 PRMC provides responds to meets 2 stipulations, decision ± days and meet times per (uploads point PRMC stipulations month. submission (with 10-day by point deadline. response response memo deadline). to IRB and

emails PRMC for

courtesy).

OUTCOMES

- 1. The PRMS worked with teams to establish uniform procedures to increase internal DOT communication and expedite response to stipulations to achieve faster time to PRMC approval. A decrease in median time from PRMC submission to PRMC approval by 2 days overall.
- 2. The PRMS enhanced the SharePoint site educational resources with links to self-help modules and reference material for study submissions.
- DOTs held study team meetings within 3 business days following PRMC meetings to complete stipulation responses in real time.

LESSONS LEARNED

- The PRMS was able to modify current processes and identify additional processes needed to enhance expeditious review to decrease time to activation for high-priority clinical trials.
- The PRMS found that feedback to DOT leaders, investigators and study teams through interactive communication, training, and monthly accrual progress reports provided transparency and increased stakeholder engagement

FUTURE DIRECTIONS

- Will continue to collaborate with stakeholders to evaluate PRMS microprocesses, to develop best practices to expedite study submissions, reduce review timelines, and improve the overall time to study activation.
- Provide readily available educational resources and reference material.